Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

81
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
81
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

65
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

68
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68
Analgesia and Pain Management01:25

Analgesia and Pain Management

2.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.4K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

60
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
60

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of Dexmedetomidine With Dexamethasone for Extended Pain Relief in Adductor Canal/Popliteal Nerve Block During Achilles Tendon Repair.

Cureus·2021
Same author

A comprehensive review of the treatment and management of Charcot spine.

Therapeutic advances in musculoskeletal disease·2021
Same author

Declining Utilization and Inflation-Adjusted Expenditures for Epidural Procedures in Chronic Spinal Pain in the Medicare Population.

Pain physician·2021
Same author

Declining Utilization Patterns of Percutaneous Adhesiolysis Procedures in the Fee-For-Service (FFS) Medicare Population.

Pain physician·2021
Same author

Is Epidural Injection of Sodium Chloride Solution a True Placebo or an Active Control Agent? A Systematic Review and Meta-Analysis.

Pain physician·2021
Same author

Treatment and Management of Twelfth Rib Syndrome: A Best Practices Comprehensive Review.

Pain physician·2021

Related Experiment Video

Updated: Mar 2, 2026

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

13.3K

Pharmacogenomics in Pain Management.

Ramsey Saba1, Alan D Kaye2, Richard D Urman1

  • 1Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Medical School, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

Anesthesiology Clinics
|May 21, 2017
PubMed
Summary

Pharmacogenomics significantly impacts how individuals respond to pain medications. Genetic variations influence the effectiveness and side effects of opioids and NSAIDs, leading to personalized dosing recommendations.

Keywords:
AlleleGenotypeHaplotypeHeterozygousHomozygousPainPharmacogenomicsPolymorphismsSingle-nucleotide polymorphisms (SNP)

More Related Videos

Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.9K
An Experimental Paradigm for the Prediction of Post-Operative Pain PPOP
14:56

An Experimental Paradigm for the Prediction of Post-Operative Pain PPOP

Published on: January 27, 2010

22.1K

Related Experiment Videos

Last Updated: Mar 2, 2026

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

13.3K
Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.9K
An Experimental Paradigm for the Prediction of Post-Operative Pain PPOP
14:56

An Experimental Paradigm for the Prediction of Post-Operative Pain PPOP

Published on: January 27, 2010

22.1K

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology
  • Drug Metabolism

Background:

  • Interpatient variability in analgesic response is well-documented.
  • Pharmacogenomic variations, particularly in cytochrome P450 enzymes like CYP2D6, contribute significantly to this variability.
  • Certain ethnic groups exhibit higher prevalence of reduced CYP2D6 function, impacting drug metabolism.

Purpose of the Study:

  • To explore the influence of pharmacogenomics on the efficacy and safety of various analgesics.
  • To investigate the role of genetic polymorphisms in drug metabolism and transport for opioids and NSAIDs.
  • To highlight the emerging trend of genotype-guided analgesic dosing.

Main Methods:

  • Review of existing literature on pharmacogenomics and analgesic response.
  • Analysis of studies examining CYP2D6 polymorphisms and their effect on weak opioid metabolism.
  • Examination of metabolic pathways for strong opioids and their relation to individual variability.
  • Assessment of cytochrome enzyme involvement in ketamine metabolism and clinical outcomes.
  • Evaluation of CYP variants associated with adverse events from nonsteroidal anti-inflammatory drugs (NSAIDs).

Main Results:

  • CYP2D6 genotype significantly affects the interpatient variability of weak opioid efficacy.
  • Strong opioid response is influenced by drug transport and individual metabolic profiles.
  • While several cytochrome enzymes are implicated in ketamine metabolism, strong evidence linking polymorphisms to clinical outcomes is lacking.
  • Specific CYP variants increase susceptibility to adverse events associated with NSAIDs.
  • Genomic-based dosing recommendations are increasingly being developed.

Conclusions:

  • Pharmacogenomic profiling is crucial for optimizing analgesic therapy.
  • Understanding individual genetic makeup allows for more predictable and safer pain management strategies.
  • Personalized medicine approaches, guided by pharmacogenomics, are transforming analgesic administration.